welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
CureDuchenne Invests in ZappRx Platform to Streamline Specialty Prescribing for Patients Suffering from Duchenne Muscular Dystrophy
ZappRx, Inc., a digital health company that streamlines specialty medication prescribing, announced today that CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), has invested in the ZappRx platform, in order to add Duchenne to the ZappRx platform in 2019.
Duchenne muscular dystrophy is the most common and severe form of muscular dystrophy that primarily affects boys. The genetic disease causes a progressive loss of muscle strength subsequent to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down. Approximately 15,000 US patients are affected with Duchenne, with a total of 300,000 patients worldwide. While there is currently no cure, there are a growing number of specialty pharmaceuticals emerging from clinical trials which may help significantly with disease management. ZappRx and CureDuchenne’s partnership will drive a more streamlined delivery of these life-changing drugs to Duchenne patients.
rareRelated
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
-
New CRISPR technique skips over portions of genes that can cause diseaseIn a new study in cells, researchers hav...
-
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a l...
-
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
-
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
-
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...